Department of Medicine, Allergy and Clinical Immunology Section, University of Verona and Verona University Hospital, Piazzale Scuro 10, Verona 37134, Italy.
Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Largo Rosanna Benzi, 10, Genoa 16132, Italy.
Immunol Allergy Clin North Am. 2020 Nov;40(4):549-564. doi: 10.1016/j.iac.2020.07.003. Epub 2020 Sep 12.
By selectively targeting specific steps of the immune inflammation cascade, biologic drugs for severe asthma have substantially contributed to increase the standard of care, to reduce drug-related morbidity. and most importantly to ameliorate patients' quality of life. Upcoming molecules are going to provide a chance for severe phenotypes besides Th2 high through the interaction with epithelial and innate immunity. Some practical aspects including optimal treatment duration, the possibility of a dose treatment modulation, the place and relevance of ICS in best responders are still under debate. Long-term safety, especially when interacting with innate immunity needs to be further investigated.
通过有针对性地针对免疫炎症级联的特定步骤，用于重度哮喘的生物药物极大地提高了护理标准，降低了药物相关的发病率。最重要的是，改善了患者的生活质量。即将出现的分子将通过与上皮细胞和先天免疫的相互作用，为除 Th2 高以外的重度表型提供机会。一些实际问题，包括最佳治疗持续时间、剂量治疗调节的可能性、ICS 在最佳反应者中的位置和相关性等，仍在争论中。长期安全性，特别是与先天免疫相互作用时，需要进一步研究。
